Retifanlimab Vs Avelumab in Patients with Metastatic Merkel Cell Carcinoma: A Cost Utility Analysis in Italy

Authors: Gianni Ghetti, Camilla Porta, Massimiliano Povero

Source: Farmeconomia: Health Economics and Therapeutic Pathways, Vol 26, Iss 1 (2025)

Subject Terms: retifanlimab, cost-utility analysis, metastatic merkel cell carcinoma, italy, Medicine (General), R5-920

File Description: electronic resource

Relation: https://journals.seedmedicalpublishers.com/index.php/FE/article/view/1574; https://doaj.org/toc/2240-256X

Access URL: https://doaj.org/article/1765306333a44372acade2c0a12b11ca

Retifanlimab in Advanced Penile Squamous Cell Carcinoma: The Phase 2 ORPHEUS Study

Authors: García Del Muro, Xavier ^{a, ⁎}, Páez López-Bravo, David ^b, Cuéllar-Rivas, Miler Andrés ^a, Maroto, Pablo ^b, Giannatempo, Patrizia ^c, Castellano, Daniel ^d, Climent, Miguel A. ^e, P. Valderrama, Begoña ^f, Gómez de Liaño, Alfonso ^g, López-Montero, Laura ^h, Mina, Leonardo ^h, Alcalá-López, Daniel ^h, Sampayo-Cordero, Miguel ^h, Necchi, Andrea ^{i, j}

Source: In European Urology Oncology April 2025 8(2):278-286

Secondary adrenocortical insufficiency after treatment with retifanlimab: a case report

Authors: Wenjing Zhang, Li Xiao, Guangxin Zhou, Huijuan Zhu, Yongmin Bi, Junjie Du, Da Zhang

Source: Frontiers in Immunology, Vol 15 (2024)

Subject Terms: adrenocortical insufficiency, retifanlimab, immune-related endocrine event, immunotherapy, hyponatremia, Immunologic diseases. Allergy, RC581-607

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fimmu.2024.1371527/full; https://doaj.org/toc/1664-3224

Access URL: https://doaj.org/article/65ae2540a2b54537b32f7f4611f34cf6

PD‐1 inhibition with retifanlimab and/or arginase inhibition with INCB001158 in Japanese patients with solid tumors: A phase I study

Authors: Yasutoshi Kuboki, Takafumi Koyama, Nobuaki Matsubara, Yoichi Naito, Shunsuke Kondo, Kenichi Harano, Kan Yonemori, Kiyotaka Yoh, Yuan Gu, Tetsuya Mita, Xuejun Chen, Eiji Ueda, Noboru Yamamoto, Toshihiko Doi, Toshio Shimizu

Source: Cancer Medicine, Vol 13, Iss 8, Pp n/a-n/a (2024)

Subject Terms: arginase, Japan, PD‐1 inhibitor, retifanlimab, solid tumors, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2045-7634

Access URL: https://doaj.org/article/054b73aa0e9c4d059dd35a08e6fa57cd

POD1UM-303/InterAACT 2: A phase III, global, randomized, double-blind study of retifanlimab or placebo plus carboplatin–paclitaxel in patients with locally advanced or metastatic squamous cell anal carcinoma

Authors: Sheela Rao, Mark Jones, Jill Bowman, Chuan Tian, Jean-Philippe Spano

Source: Frontiers in Oncology, Vol 12 (2022)

Subject Terms: anal cancer, carboplatin, paclitaxel, retifanlimab, squamous carcinoma, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2022.935383/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/dd38624b91174dd9aeed0d706fae467a

High-resolution crystal structure of PD-1 in complex with retifanlimab, the FDA-approved immune checkpoint blocking antibody for treating Merkel cell carcinoma

Authors: Cho, Seong-Ha, Park, Jeong-Min, Lee, Eun Ho, Song, Ye Han, Jang, Yu-Jeong, Choi, Seung-Beom, Heo, Yong-Seok ^⁎

Source: In Biochemical and Biophysical Research Communications January 2025 742

FDA Approves Retifanlimab-Dlwr for the Treatment of Metastatic or Recurrent Locally Advanced MCC

Authors: By:Kaitlyn Bader, Editor

Source: Dermatology Times (USA), March 22, 2023 News, 3pp

FDA Approves Retifanlimab-dlwr for Merkel Cell Carcinoma

Authors: By:Hayley Virgil

Source: CancerNetwork (USA), March 22, 2023 News, 2pp

FDA Grants Accelerated Approval to Retifanlimab for Locally Advanced Merkel Cell Carcinoma

Authors: By:Lindsay Fischer

Source: Oncology Nursing News (USA), March 22, 2023 News, 3pp

Early Data Show Ongoing Benefit of Bria-IMT in Small Breast Cancer Population

Authors: By:Nicholas Wrigley

Source: CancerNetwork (USA), March 20, 2023 News, 3pp

BriaCell announces new patent issuance, Bria-OTS IND timing guidance, and additional clinical sites to boost enrolment.

Source: Chemical Business NewsBase (UK), January 10, 2023, 3pp

BriaCell reports positive breast cancer efficacy data with Bria-IMT immunotherapy treatment at SITC Annual Meeting.

Source: Chemical Business NewsBase (UK), November 10, 2022, 3pp

BriaCell announces successful completion of Phase I portion of clinical study in advanced breast cancer; randomized Phase II efficacy evaluation progressing.

Source: Chemical Business NewsBase (UK), October 21, 2022, 2pp

MacroGenics shutters Phase II cancer study following 7 patient deaths.

Source: Chemical Business NewsBase (UK), July 11, 2022, 3pp

BriaCell receives FDA Fast Track Approval for targeted breast cancer immunotherapy.

Source: Chemical Business NewsBase (UK), April 13, 2022, 2pp

FDA rejects Incyte's PD-1 for anal cancer, requires more proof of benefit.

Source: Chemical Business NewsBase (UK), July 26, 2021, 2pp

MacroGenics provides update on corporate progress and 1Q 2021 financial results. [2 tables in original article]

Source: Chemical Business NewsBase (UK), April 29, 2021, 3pp

Incyte announces the validation by the European Medicines Agency of its Marketing Authorization Application for retifanlimab as a treatment for patients with squamous cell anal carcinoma (SCAC).

Source: Chemical Business NewsBase (UK), February 26, 2021, 2pp

MacroGenics announces achievement of $10 M milestone related to retifanlimab collaboration with Incyte.

Source: Chemical Business NewsBase (UK), February 11, 2021, 3pp

Incyte announces acceptance and priority review of BLA for retifanlimab as a potential treatment for patients with squamous cell carcinoma of the anal canal (SCAC).

Source: Chemical Business NewsBase (UK), January 21, 2021, 2pp